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lesion types. The first reflects complement deposition at the 
surface of astrocytes, associated with granulocyte infiltra-
tion and astrocyte necrosis and followed by demyelination, 
global tissue destruction and the formation of cystic, necrotic 
lesions (lesion type 2). Such destructive lesions lead to Wal-
lerian degeneration in lesion-related tracts (lesion type 3). 
Around active NMO lesions AQP4 may selectively be lost 
in the absence of aquaporin 1 (AQP1) loss or other struc-
tural damage (lesion type 4). Another pattern is character-
ized by clasmatodendrosis of astrocytes, defined by cyto-
plasmic swelling and vacuolation, beading and dissolution 
of their processes and nuclear alterations resembling apop-
tosis, which was associated with internalization of AQP4 
and AQP1 and astrocyte apoptosis in the absence of comple-
ment activation. Such lesions give rise to extensive astrocyte 
loss, which may occur in part in the absence of any other 
tissue injury, such as demyelination or axonal degeneration 
(lesion type 5). Finally, lesions with a variable degree of 
astrocyte clasmatodendrosis are found, which show plaque-
like primary demyelination that is associated with oligoden-
drocyte apoptosis, but with preservation of axons (lesion 
type 6). In active multiple sclerosis (MS) lesions astrocytes 
reveal changes of reactive protoplasmatic or fibrillary glio-
sis. Only in a subset of lesions, in patients with aggressive 
disease, loss of AQP4 is observed in the initial stage of their 
formation, which is associated with retraction of astrocyte 
processes in the absence of complement deposition, granu-
locyte infiltration or loss of AQP1 or astrocytes. Our data 
underline the primary assault of astrocytes in NMO lesions, 
but also indicate that different mechanisms of tissue injury 
operate in parallel in the same patient and even within the 
same lesion.
Keywords Neuromyelitis optica · Astrocytes · 
Demyelination · Complement
Abstract Neuromyelitis optica (NMO) is an autoimmune 
disease targeting aquaporin 4 (AQP4), localized mainly at 
the astrocytic foot processes. Loss of AQP4 and glial fibril-
lary acidic protein (GFAP) was reported, but the patho-
logical significance of astrocytopathy is still controversial. 
Here we show that active lesions in NMO display a wide 
spectrum of pathology even within a single tissue block of 
an individual patient. We have distinguished six different 
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Abbreviations
AQP1  Aquaporin 1
AQP4  Aquaporin 4
GFAP  Glial fibrillary acidic protein
NMO  Neuromyelitis optica
MS  Multiple sclerosis
EAAT2  Excitatory amino acid transporter 2
CNS  Central nervous system
PBS  Phosphate buffered saline
FCS  Fetal calf serum
Introduction
Neuromyelitis optica (NMO) is a chronic inflamma-
tory disease of the central nervous system, resulting in 
demyelinating and destructive lesions predominantly in 
the spinal cord and the optic system [6, 28]. Recently, 
auto-antibodies directed against the astrocyte water chan-
nel aquaporin 4 (AQP4) have been discovered in NMO 
patients, which turned out to be a highly specific and 
sensitive paraclinical diagnostic marker of the disease 
[11, 25, 26]. Furthermore, the potential pathogenicity of 
these auto-antibodies has been shown in in vitro and in 
vivo experiments [2, 3, 20, 42, 46]. From these data it 
is now well established that AQP4 antibodies, when get-
ting access to the central nervous system compartment 
in vivo, can destroy astrocytes [8]. It is assumed that the 
antibodies drive complement-dependent lysis, and that 
granulocytes and eosinophils recruited into the lesions 
are major effector cells [42]. Demyelination and axonal 
destruction may in part be mediated by excitotoxic mech-
anisms, which may develop when the excitatory amino 
acid transporter 2 (EAAT2) is lost from dysfunctional 
astrocytes [13, 30]. In addition, loss of AQP4 from astro-
cytes may disturb water homeostasis and result in brain 
edema [12, 14]. However, to what extent these concepts, 
mainly developed in in vitro models, are also operating 
in the patient’s lesions in vivo, is less clear. In addition, 
it remains to be determined, whether similar mechanisms 
of tissue injury are also relevant for the development 
of demyelinating lesions in multiple sclerosis patients 
[38]. This question has gained further attention, since 
it has recently been described that about half of all MS 
patients have circulating autoantibodies against a potas-
sium channel expressed on astrocytic foot processes (Kir 
4.1), and that these antibodies may destroy astrocytes in 
vitro in a complement-dependent manner [50]. In this 
study we performed a detailed comparison of astrocyte 
pathology in relation to demyelination and neurodegen-
eration in active NMO and MS lesions. As described 
before [31, 35, 36, 43], our studies show that astrocyte 
pathology is unique and highly characteristic in NMO, 
but that different mechanisms lead to astrocyte destruc-
tion, demyelination and neurodegeneration. In contrast, 
we did not find evidence for antibody or complement-
mediated astrocyte injury in MS lesions.
Materials and methods
Cases and material
This study was performed on paraffin-embedded, formalin-
fixed archival material of active lesions from NMO patients 
(n = 7), from multiple sclerosis patients, including acute 
MS (n = 6), secondary progressive MS (n = 6) and pri-
mary progressive MS (n = 6), and non-neurological con-
trols (n = 3; Table 1). The cases were selected from a much 
larger sample of archival autopsy material, collected in the 
Department of Neurology at the Tohoku University School 
of Medicine and the Brain Research Institute at the Univer-
sity of Vienna, on the basis of presence of active lesions and 
suitability for detailed immunohistochemical investigations. 
From the NMO cases, four cases fulfilled the Wingerchuck 
[56] clinical criteria of definite NMO (499, 216, A10-42 and 
2001-50), two of a limited form of NMO (12193 and A10-
36) and one case (24–81) presented with a single destructive 
lesion in the medulla oblongata, with NMO typical pathol-
ogy [28]. Since half of the NMO patients died before tests 
for AQP4 antibodies were available, pathological diagnostic 
criteria for NMO were used, which included lesional topog-
raphy, the presence of longitudinally extensive lesions in the 
spinal cord mainly affecting grey matter, of active lesions 
with marked inflammation and tissue damage in vasculo-
centric pattern, and/or destructive inflammatory lesions with 
extensive loss of astrocytes, associated with demyelination 
and profound axonal destruction [28]. In contrast, all MS 
patients showed focal inflammatory demyelinating lesions 
throughout the central nervous system (CNS) and a variable 
extent of cortical demyelination and diffuse white matter 
injury [22]. In addition, clinical history and results of whole 
body autopsy, where available, were reviewed. The study 
was approved by the Ethic Commission of the Medical Uni-
versity of Vienna (Nr. 087/01/2012) and the Tohoku Univer-
sity Graduate School of Medicine (No. 2009-143/2011-74).
Neuropathological techniques and immunohistochemistry
The brain and spinal cords were fixed with 10 % forma-
lin and multiple tissue blocks were embedded in paraffin. 
Tissue slices of 4–6 μm thickness were cut and mounted 
serially on numbered slides. Histological examinations 
were performed by hematoxylin and eosin (HE), Klüver-
Barrera (KB), and Bielschowsky’s silver impregnation 
axonal stain.
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Sections were deparaffinized twice with xylol substitute 
(XEM) (Fluka analytical, Germany) for 20 min each, rinsed 
twice in 96 % ethanol, treated with hydrogen peroxide in 
methanol for 30 min to block endogenous peroxidases, rehy-
drated in a descending series of ethanol and further incu-
bated for 1 h in phosphate buffered saline containing 10 % 
fetal calf serum (PBS/FCS) to block nonspecific antibody 
binding. Antigen retrieval was performed by heating the 
sections for 60–90 min in EDTA (1 mM EDTA, 10 mM Tris, 
pH 8.5 or 9) or 0.1 mM citrate buffer (pH 6) in a household 
food steamer device. The primary antibodies (Table 2) were 
applied overnight in PBS/FCS. Afterwards, the slides were 
washed 3–4 times in PBS. Then the slides were incubated 
with biotinylated secondary antibodies (sheep anti-mouse, 
donkey anti-rabbit, donkey anti-goat; all from Amersham 
or Jackson ImmunoResearch) for 1 h at room temperature. 
After washing 3–4 times in PBS, the sections were treated 
with avidin peroxidase (diluted 1:100 in 10 % FCS/PBS), 
and incubated for 1 h at room temperature. For visualization 
of the bound antibodies, diaminobenzidine (DAB) was used 
as chromogen.
For double staining, we combined two enzyme systems, 
peroxidase and alkaline phosphatase. After the single stain-
ing procedure using anti-mouse antibody, we further applied 
rabbit anti-human antibody and then incubated the sections 
with AP-conjugated anti-rabbit IgG and stained by Vector 
blue. Counter staining was done by hematoxylin or nuclear 
fast red, where applicable.
In human brain and spinal cord tissue astrocytes express 
besides AQP4 another water channel, i.e. aquaporin 1 
(AQP1; Supplementary Figure 1; [48]). This is differ-
ent from rodent CNS tissue, where AQP1 is exclusively 
expressed on the epithelial cells of the choroid plexus [24]. 
Since AQP1 is highly expressed in the human CNS in areas, 
Table 1  Demographics of NMO, MS and control patients
Case Age Gender Dis.Dur. AQP-4 Ab Les. Location Les. Type
499 20 Female 4 years n.d. SC, O, Brain 1, 2, 3, 4, 5, 6
216 30 Female 5 years n.d. SC, Med. 1, 2, 4, 5
24-81 46 Female 0.5 months n.d. Med. 1, 2
12193 57 Female 8 months Positive SC, Med. 2, 4, 5, 6
A10-42 75 Female 21 years Positive SC, O 4
A10-36 82 Female 10 years Positive SC, Brain 4, 6
2001-50 63 Female 20 years n.d. SC, O 1, 2, 3, 4, 5, 6
AMS 1 34 Female 4 months n.d. Brain DM, p. AQP4 loss
AMS 2 35 Male 1.5 months n.d. SC, Med, Brain DM, p. AQP4 loss
AMS 3 45 Male 0.2 months n.d. Brain DM, p. AQP4 loss
AMS 4 45 Male 0.6 months n.d. Brain DM, p. AQP4 loss
AMS 5 52 Male 1.5 months n.d. Brain DM, RG
AMS 6 78 Male 2 months n.d. Med, Brain DM, RG
SPMS 1 34 Male 120 months n.d. SC, Med, Brain DM, RG
SPMS 2 41 Male 137 months n.d. Med, Brain DM, RG
SPMS 3 46 Female 444 months n.d. SC, Med, Brain DM, RG
SPMS 4 53 Female 241 months n.d. Brain DM, RG
SPMS 5 56 Male 372 months n.d. Med, Brain DM, RG
SPMS 6 66 Female 96 months n.d. Brain DM, RG
PPMS 1 34 Male 204 months n.d. Med, Brain DM, RG
PPMS 2 53 Male 168 months n.d. Brain DM, RG
PPMS 3 54 Female 72 months n.d. Brain DM, RG
PPMS 4 55 Female 60 months n.d. Brain DM, RG
PPMS 5 67 Male 87 months n.d. Med, Brain DM, RG
PPMS 6 71 Female 264 months n.d. Brain DM, RG
CO1 39 Female 0 n.d. 0
CO2 45 Female 0 n.d. 0
CO3 30 Female 0 n.d. 0
Dis.Dur disease duration, Les.Locat lesion location, Les.Type lesional type, AMS acute multiple sclerosis, SPMS secondary progressive multiple 
sclerosis, PPMS primary progressive multiple sclerosis, CO controls, SC spinal cord, O optic nerve, Med medulla oblongata, DM demyelinated 
lesions, p AQP4 loss partial aquaporin 4 loss, RG reactive gliosis
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destined to develop NMO lesions (Supplementary Figure 1) 
and is also present on the surface of astrocytes within NMO 
lesions, we used this protein as an additional marker to ana-
lyse the astrocyte reaction within the lesions.
TUNEL staining
For the detection of cell death, we used the in situ cell death 
detection kit AP (Roche Applied Science, German). Briefly, 
dewaxed and rehydrated sections were covered by TUNEL 
reaction mixture for 60 min. After washing with PBS for 
3 times, converter-AP was added on the slides for 30 min. 
After washing, the immunostaining was performed by 
Vector blue.
Results
Global pathology of active NMO lesions
Active lesions in both NMO and MS were defined by the 
presence of early CNS protein reactive degradation prod-
ucts in macrophages, as defined before in multiple sclero-
sis lesions [4]. In contrast to MS lesions, macrophages in 
active NMO lesions also contained GFAP reactive degra-
dation products. All NMO cases included in this sample 
contained active lesions together with inactive destructive 
or demyelinated lesions at other sites of the central nervous 
Table 2  Antigen retrieval and primary antibodies
Antibody Origin Target Dilution Antigen retrieval Source
AQP-1 Rabbit (pAB) Aquaporin-1 1:500 0 Sc-20810; Santa Cruz, 
USA
AQP-4 Rabbit (pAB) Aquaporin 4 1:250 0 Sigma-Aldrich, St. Louis, 
USA
C9neo Rabbit (pAB) Complement component C9 1:2,000 P [39]
CD68 Mouse (mAB) 110-kD Transmembrane  
glycoprotein
1:100 St (E) M0814; Dako,  
Glostrup, Denmark
GFAP Rabbit (pAB) Glial fibrillary  
acidic protein
1:3,000 St (E) Z0334; Dako, Glostrup, 
Denmark
Ig Sheep (pAB) Human  
immunoglobulin
1:200 P RPM1003; Amersham 
Pharmacia Biotech, 
Buckinghamshire, UK
MBP Rabbit (pAB) Myelin basic  
protein
1:2,500 0 A0623; Dako, Glostrup, 
Denmark
NF Rabbit (pAB) Neurofilament  
medium chain (150 kDa)
1:2,000 St (E) AB1981; Chemicon, 
Temecula, CA, USA
PLP Mouse (mAB) Proteolipid protein 1:1,000 St (E) MCA839G; Serotec, 
Düsseldorf, Germany
MAG Mouse (mAB) Myelin associated  
glycoprotein
1:1,000 St (E) AB B11F7 [27]
TPPP/p25 Rabbit (pAB) Tubulin polymerization  
promoting protein;  
Oligodendrocytes
1:250 St (E) [15]
MOG Mouse (mAB) Myelin associated  
glycoprotein
1:1,000 St (C) AB 8-18C5 [27]
pAB polyclonal antibody, mAB monoclonal antibody, St antigen retrieval in steamer, E EDTA buffer, C citrate buffer, P antigen retrieval with 
protease
Fig. 1  Different lesion types in the central nervous system of NMO 
patients: a–h distribution of different lesion types in the spinal cord 
of patients with neuromyelitis optica (patient 499, spinal cord). The 
different lesion types are characterized by different types of astro-
cyte pathology, demyelination, axonal injury, inflammation and com-
plement C9neo deposition. The position of different lesion types, 
as characterized in detail in Figs. 1 and 2 are labeled by numbers in 
the sections stained for myelin (a); ×5. i–q Lesion type 1 is defined 
by extensive complement deposition and granulocyte infiltration (i); 
astrocytes are in part preserved and express AQP1, but have nearly 
completely lost AQP4 (j–l); degenerating astrocytes show C9neo 
reactivity on their surface (m) and fragmented TUNEL-positive DNA 
in the nucleus and dispersed in the cytoplasm, suggesting necrotic 
cell death (n); myelin (o) and axons (p) are partly preserved, but dys-
trophic swollen axonal spheroids are present (p), which have accu-
mulated amyloid precursor protein (APP; q). i–l and o–q ×250; m, 
n ×1,100; r–w lesion type 2 reflects a destructive lesion with exten-
sive loss of astrocytes (r, s), and liberation of GFAP rich exudates 
into the extracellular space (r); insert in r shows complement C9neo 
in macrophages; more advanced lesions t–w show cystic cavities 
with some macrophages and tissue bridges containing astrocytes (u), 
which have lost AQP4 (v) and axons (w), but being devoid of myelin 
myelin (t); r, s ×150; t–w ×250
▸
819Acta Neuropathol (2013) 125:815–827 
1 3
820 Acta Neuropathol (2013) 125:815–827
1 3
system (Fig. 1). Active lesions in NMO showed profound 
inflammation. Inflammatory infiltrates were composed of T 
lymphocytes, B lymphocytes and macrophages. Profound 
microglia activation was seen in the periplaque white mat-
ter in both conditions. Inflammatory infiltrates were in part 
concentrated around vessels (perivascular cuffs) and in part 
dispersed throughout the lesion parenchyme. Abundant neu-
trophilic granulocytes and some eosinophils were present in 
a subset of active NMO lesions [28].
A more detailed inspection of sections with active NMO 
lesions, however, revealed that at least six different lesion 
types were present, suggesting different type- and stage-
specific patterns of tissue injury (Table 3). They differed in 
the extent of complement deposition, granulocyte infiltra-
tion, acute astrocyte alterations, astrocyte loss, demyelina-
tion and axonal injury. They were found in the spinal cord 
and brain stem of all patients and also, when lesions were 
present at all, in the forebrain (Supplementary Figure 2). 
The different lesion types appeared in part side by side 
within the same tissue block (Fig. 1a–h), but their relative 
number in different brain regions of the same patient and of 
different patients varied (Supplementary Figure 2).
Active NMO lesions associated with complement activation 
and granulocyte infiltration (lesion type 1)
The first lesion type was characterized by massive depo-
sition of immunoglobulins and activated complement and 
high infiltration of the tissue by granulocytes (Fig. 1i). In 
such lesions astrocytes and their processes were covered in 
part with activated complement (Fig. 1m), and perivascular 
astrocyte processes were partly lost. The remaining GFAP 
positive astrocytes did not show AQP4 on their surface, but 
in part still expressed AQP1 (Fig. 1j–l). TUNEL staining 
showed DNA fragmentation in the nuclei of such astrocytes 
and TUNEL-positive DNA was also diffusely dispersed 
within the cytoplasm, a pattern characteristic for cell necro-
sis (Fig. 1n). Myelin and axons were relatively spared in 
comparison to astrocyte loss, but active demyelination and 
axonal injury was documented by apoptotic oligodendro-
cytes and by the presence of macrophages with early myelin 
degradation products together with acutely injured axons 
with accumulation of amyloid precursor protein and neuro-
filament reactivity in axonal spheroids (Fig. 1o–q). Analy-
sis of different myelin antigens revealed little or no loss of 
myelin basic protein, proteolipid protein or myelin oligo-
dendrocyte glycoprotein, while myelin associated glycopro-
tein was lost from most myelin sheaths [5] and oligodendro-
cytes were massively reduced in numbers within the lesions 
(Supplementary Figure 3).
Cystic lesions with extensive tissue destruction  
(lesion type 2)
In these areas most cellular components were lost and 
replaced by fluid filled cysts, which contained a variable 
number of macrophages and vessels with perivascular fibro-
sis (Fig. 1r–w). If such lesions still contained active areas 
of lesion type 1, C9neo antigen was present on astrocyte 
processes or in degradation products in macrophages at the 
Table 3  Key pathological 
features of different lesions 
types in NMO
Les. Type T Gr C9n AG Demy OG loss Ax 
loss




2 +/++ ± ± AQP4 loss Complete +++ +++
AQP1 loss
GFAP loss
3 – – – React. gliosis +++ ++ +++
4 ± – – AQP4 loss – – –
Clasmatodendrosis +








Les.Type lesion type, T T 
cells, Gr granulocytes, C9n 
complement C9neo antigen, 
AG astroglia pathology, Demy 
demyelination, OG loss loss 
of oligodendrocytes, Ax. Loss 
axonal loss
±, minor or absent; +, minor; 
++, moderate; +++, severe
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lesion borders. Within the inactive center of such lesions 
some bridges of preserved tissue remained between the 
cystic cavities, which contained astrocytes and axons, but 
no myelin sheaths and only sparse oligodendrocytes (Sup-
plementary Figure 3). AQP1 and AQP4 expression was 
largely lost within cystic lesions. When such lesions were 
present side by side with active lesions the cysts contained a 
protein-rich fluid, which was highly reactive for GFAP but 
not for aquaporins (Fig. 1r, s). This was no longer the case in 
more advanced destructive lesions (Fig. 1t–w).
Lesions resembling secondary Wallerian degeneration 
(lesion type 3)
Such lesions were present in white matter tracts of the spi-
nal cord. They showed an extensive loss of myelin, oligo-
dendrocytes and axons and a profound fibrillary gliosis 
with densely packed GFAP and AQP1 reactive astrocytic 
processes, while loss of AQP4 was variable (Fig. 2a–c, 
Supplementary Figure 3).
Lesions with selective loss of AQP4 in the absence of other 
structural damage (lesion type 4)
This pattern of tissue injury was frequently seen in the 
vicinity of active NMO lesions. They were associated with 
mild to moderate perivascular inflammatory infiltrates and 
a variable degree of microglia activation, but no comple-
ment deposition or granulocyte infiltration. In sections 
stained for conventional cellular markers, myelin or axons, 
no pathological alterations were seen (Fig. 2d, Supplemen-
tary Figure 3). However, immunohistochemistry for AQP4 
revealed profound or even complete loss of this protein on 
astrocytes, which still normally expressed AQP1 and GFAP. 
GFAP positive astrocytes either showed a normal structure 
and the presence of cell processes within the perivascular 
glia limitans. However, some of them were enlarged with 
increased perinuclear GFAP reactivity and contained intra-
cytoplasmic granular AQP4 reactivity, suggesting endo-
cytotic uptake (Fig. 2d–g) probably due to the AQP4Ab-
induced internalization.
Active NMO lesions with astrocytic clasmatodendrosis 
(lesion type 5)
In these lesions, inflammatory infiltrates mainly consisted 
of T cells and macrophages. Reactivity for activated termi-
nal complement on astrocytes and granulocyte infiltration 
were absent at the site of astrocyte injury. The characteristic 
hallmark of such lesions was the accumulation of bizarre 
astrocytes with massively enlarged peri-nuclear cytoplasm, 
presence of intra-cytoplasmic vacuoles and retraction, bead-
ing and clumping of the cell processes. AQP4 reactivity 
was partially lost from the surface of such astrocytes, but 
the cells contained abundant intracellular granules, reactive 
for AQP4, AQP1 and immunoglobulins. Many of these cells 
showed dense and condensed nuclei with DNA fragmenta-
tion, thus resembling apoptotic cells. Myelin sheaths, reac-
tive for MBP, PLP and MAG, oligodendrocytes and axons 
were well preserved in the majority of these lesions, thus the 
presence of such lesions was not visible in sections stained 
for myelin (Fig. 2h–q, Supplementary Figure 3).
Lesions with astrocyte dystrophy and primary 
demyelination (lesion type 6)
These lesions were sharply demarcated areas of complete 
demyelination, loss of oligodendrocytes and axonal preser-
vation (Fig. 2r–y, Supplementary Figure 3). Active demyeli-
nation was reflected by the presence of macrophages with 
early myelin degradation products. Also in these lesions 
prominent inflammation was present mainly consistent of T 
cells and macrophages. Granulocytes and deposition of acti-
vated complement were absent. GFAP positive astrocytes 
were present in the lesions in variable extent, and immu-
noreactivity for AQP1 and AQP4 showed more pronounced 
reduction compared to GFAP. Furthermore, astrocyte clas-
matodendrosis, as described in lesion type 2, was seen in 
some of the remaining GFAP positive astrocytes.
Astrocyte pathology in multiple sclerosis lesions
Active lesions dominated the pathology of acute MS 
(Fig. 3), although also a variable number of inactive lesions 
were present. In patients with progressive MS, classical 
active lesions were rare, while slowly expanding as well as 
inactive lesions were seen in variable numbers [21]. Active 
as well as slowly expanding lesions showed inflammation, 
mainly consistent of T cells and macrophages/microglia 
[7], but granulocytes and eosinophils were rarely seen. As 
described in detail before ([23], Fig. 3a–c) primary demyeli-
nation with oligodendrocyte apoptosis was the hallmark of 
initial tissue injury in active MS lesions. Furthermore, pref-
erential loss of myelin-associated glycoprotein was promi-
nent in active lesions of acute MS [27].
Concerning astrocytes, slowly expanding and inactive 
lesions in MS showed the MS-typical glial scar. Reactive 
astrocytes expressed GFAP, AQP4 and AQP1. However in a 
subset of fulminate active lesions in acute MS, loss of AQP4 
was encountered, associated with the appearance of large 
protoplasmatic, sometimes multi-nucleated astrocytes, with 
retraction of perivascular astrocytic foot processes from the 
glia limitans (Fig. 3; [32, 33, 49]). These protoplasmatic 
astrocytes were intensely stained for GFAP and highly 
expressed AQP1. Furthermore, in immediately adjacent 
areas massive over-expression of AQP4 was seen around the 
822 Acta Neuropathol (2013) 125:815–827
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cell body and proximal processes of some of the reactive 
astrocytes. Morphological signs of necrosis or apoptosis as 
well as evidence for DNA fragmentation in astrocytes were 
absent and no activated complement was detected on these 
cells (Fig. 3d–g).
Discussion
The specific features in acute stages of NMO lesions are the 
loss of AQP4 [35, 36, 43] and the perivascular or subpial 
deposition of humoral factors such as immunoglobulin IgG 
and IgM, or activated complement (C9neo; [28, 43]). This 
apparently reflects a humoral immune attack against the glia 
limitans especially against the astrocyte foot processes by 
AQP4 reactive auto-antibodies. Based on these observa-
tions and experimental evidence it has been suggested that 
blockade of terminal complement activation, of Fc-recep-
tor-mediated, antibody-dependent cellular cytotoxicity or 
of the recruitment of neutrophils and eosinophils should 
be followed as therapeutic strategies in NMO patients with 
active disease [42, 47, 53].
Fig. 2  Different lesion types in the central nervous system of 
NMO patients [2]: a–c lesion type 3 represents areas of Wallerian 
degeneration; myelin sheaths (a) and axons (b) are lost in compa-
rable degree; there is profound astrocytic gliosis (c); the astrocytes 
express GFAP and AQP1 and 4; (patient 499, spinal cord) ×30. 
d–g Lesion type 4 shows selective loss of AQP4 (e), while myelin 
sheaths (d), axons and neurons remain preserved; reactive astro-
cytes express GFAP (g) and AQP1 (f); some astrocytes also show 
granular intra-cytoplasmic reactivity for AQP4 (e, insert); (patient 
499 spinal cord), ×250; insert: ×1,100. h–q lesion type 5 shows 
extensive loss of astrocytes (h) and astrocytic clasmatodendro-
sis (l–q), while myelin sheaths (i) and axons are preserved; there 
is profound macrophage infiltration (k), but no deposition of acti-
vated complement or granulocyte infiltration (j); astrocyte clasma-
todendrosis is characterized by enlargement or peri-nuclear astro-
cyte cytoplasm and clumping and beading of cell processes (l–q), 
granular internalization of AQP1 (n), AQP4 (l, m) and IgG (p) and 
condensed nuclei (m, n, p) with DNA fragmentation (apoptosis; q); 
h–k (patient 216, medulla); ×50; l–q ×1,100. r–y Lesion type 6 is 
characterized by selective primary demyelination (r), axonal preser-
vation (s), profound astrocytic gliosis (t) and a variable expression 
of AQP4 (u). AQP4 is lost in adjacent areas, which show features of 
complement-mediated active tissue destruction (adjacent lesion 1; 
Fig. 1a) or a destructive lesion pattern 2 (adjacent lesion 2, Fig. 1a); 
active demyelination is associated with macrophage infiltration (v); 
astrocytes show partial loss of AQP4 (y) and AQP1 (w) and some 
astrocytes with clasmatodendrosis (x, y); r–u (patient 499, spinal 
cord); ×20; v–y ×150
◂
Fig. 3  Astrocyte pathology in an aggressive active demyelinat-
ing lesion of acute MS: a–c large subcortical lesion with ill defined 
borders and some concentric banding of demyelination at the lesion 
edge (a) is associated with profound inflammation (b) and protoplas-
matic astrocyte reaction (c). a ×2; b, c ×150. d–g Astrocyte pathol-
ogy shown by double staining for AQP1 (blue) and AQP4 (brown); in 
the normal appearing white matter reactive astrocytes express AQP1 
and AQP4 (d, left); in the active zone there is a concentric layering of 
AQP4 loss (blue cells) and adjacent zones with AQP1-reactive astro-
cytes that strongly express AQP4; e–g show higher magnifications of 
the areas shown in d. d ×300; e–g ×900
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In this study, we show that tissue injury in the brain and 
spinal cord of NMO patients is complex and is mediated by 
at least two different mechanisms. In the first (lesion type 
I), active tissue injury is associated with antibody deposi-
tion and complement activation on astrocytes and their pro-
cesses and this process is associated with profound recruit-
ment of granulocytes and some eosinophils. This pattern 
can be well reproduced in in vivo rodent models, mediated 
by NMO antibodies in animals with autoimmune encepha-
lomyelitis [3] as well as after local injection of NMO IgG 
into the mouse brain together with human complement 
[46]. Such lesions are in close topographical relation with 
inactive destructive lesions (lesion type 2) and we suggest 
that global overt tissue destruction and the formation of 
cystic cavities is the direct consequence of complement and 
granulocyte-induced tissue injury. In addition, the lack of 
astrocytes expressing the excitatory amino acid transporter 
(EAAT2) may promote excitotoxicity due to excess gluta-
mate in the extracellular space [13, 30]. Interestingly, the 
cystic cavities in early stages of destructive lesions contain a 
protein-rich fluid, which is highly reactive for GFAP. Thus, 
liberation of soluble GFAP through necrotic destruction of 
astrocytes may be the reason for high GFAP levels in the 
patient’s cerebrospinal fluid during active phases of the dis-
ease [37, 51]. Furthermore, extensive axonal destruction in 
such necrotizing lesions will result in secondary Wallerian 
tract degeneration in rostral or caudal segments of the spinal 
cord (lesion type 3).
A second type of lesions (type 4 and 5) apparently devel-
oped in the absence of complement activation and granulo-
cyte infiltration at the site of active tissue injury. This type of 
tissue injury affected astrocytes leaving other components 
of the nervous tissue unaffected. It was reflected either by 
selective loss of AQP4 on astrocytes (lesion type 4) or by 
profound astrocyte loss associated with degenerative astro-
cyte alterations at the lesion edge (lesion type 5).
As described before [35, 36, 43] astrocytes, which are 
still preserved around NMO lesions, may lose AQP4 from 
their surface. The functional significance of pure AQP4 loss 
is currently not clear. It has been suggested that such astro-
cytes are functionally impaired with respect to control of 
water homeostasis [12], although these in vitro results could 
not be confirmed by others [44]. In addition, in the human 
brain and in such NMO lesions, but not in the rodent CNS, 
astrocytes also express AQP1, which is similarly efficient 
in regulating water transport in comparison to AQP4 [14].
In lesions with astrocyte loss, the characteristic hallmark 
for tissue injury was loss of AQP4 and a pattern of astrocyte 
dystrophy, which bears similarities to astrocyte clasmato-
dendrosis. Clasmatodendrosis was initially described in 
the beginning of the 20th century, as a regressive morpho-
logical change of astrocytes with cytoplasmic swelling and 
vacuolation with beading and dissolution of their dendritic 
processes [16]. Recently, clasmatodendrosis has been rec-
ognized to be associated with various diseases such as vas-
cular diseases including Binswanger’s leukoencephalopathy 
[10, 52] or epilepsy [19]. It appears to reflect a regressive 
change of astrocytes, which can be induced by several 
mechanisms, such as for instance energy deficiency [16, 
19] or autophagic cell death [45], and which may finally 
result in astrocyte apoptosis [19]. In NMO this alteration of 
astrocytes seems to be directly induced by AQP4 antibod-
ies in the absence of complement. This is supported by our 
finding that this type of astrocyte injury is associated with 
intra-cytoplasmic accumulation of AQP4, AQP1 and IgG-
positive granules, apparently reflecting endosomal internali-
zation of antibody-opsonized portions of the astrocyte cell 
membrane. Similar astrocyte changes have been described 
before in active NMO lesions [14]. We show further that 
many of the astrocytes with such alterations have shrunken, 
condensed and sometimes fragmented nuclei, which contain 
fragmented DNA. These changes are typical for apoptosis. 
Thus, there is apparently a pathway of astrocyte destruction 
in NMO lesions, which is different from complement and 
granulocyte mediated lysis. Interestingly, this disturbance 
and loss of astrocyte was not necessarily associated with 
demyelination nor neurodegeneration, which is in line with 
previous observations [41].
In addition we found lesions (lesion type 6) in NMO 
patients, characterized by complete demyelination and 
axonal preservation. Astrocytes within these lesions were 
present, but some showed changes of clasmatodendrosis, 
described above. It is likely that in these lesions, as in the 
destructive complement-mediated lesions, oligodendrocyte 
injury and demyelination follows astrocyte injury and loss. 
Interestingly, initial alterations of oligodendrocytes and 
myelin, consistent of oligodendrocyte apoptosis and loss 
of distal oligodendrocyte processes, which had originally 
been defined in a subset of active multiple sclerosis lesions 
[27], are also seen in actively demyelinating NMO lesions 
[5]. It has, thus, been suggested that in NMO as well as in 
MS, demyelination may follow an initial astrocyte injury 
[38]. Astrocytes are important for creating a homeostatic 
environment for oligodendrocytes. Energy demand of oli-
godendrocytes and axons is in part provided by astrocytes, 
transferring lactate through gap junctions to oligoden-
drocytes [9]. Loss of gap junction-related connexins that 
are expressed on astrocytes or oligodendrocytes has been 
found in active lesions of MS and NMO [34, 49]. In addi-
tion, astrocytes express the excitatory amino acid trans-
porter 2 (EAAT2), which removes toxic glutamate from the 
extracellular space and can, thus, reduce excitotoxic cell 
death of neurons and oligodendrocytes [30]. Since demy-
elination in a subset of MS lesions is associated with oxida-
tive damage, mitochondrial injury [29] and a state of virtual 
hypoxia [1], it could also be that such lesions are induced 
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in both conditions by additional hypoxia-like mechanisms. 
In NMO, severe tissue edema may impair blood microcir-
culation. In addition, oxidative damage and hypoxia-like 
tissue injury can be amplified by glutamate toxicity, which 
is expected to occur in such NMO lesions due to the loss of 
EAAT2 [13, 30].
Although loss of AQP4 has been described before in 
actively demyelinating lesions in a subset of MS patients 
[32, 33, 49] and was also seen in this study, this was not 
associated with complement activation, granulocyte infil-
tration, astrocyte destruction or loss [35, 43] or astrocyte 
clasmatodendrosis. AQP4 loss in this condition rather 
reflected retraction of perivascular astrocyte processes, 
similar to that present in CNS lesions induced by severe 
innate immunity-driven inflammation [49]. The lack of 
astrocyte loss or complement deposition does not sup-
port the view that antibodies against Kir 4.1, which have 
recently been described in around 47 % of all MS patients 
[50], destroy astrocytes in the lesions in a complement-
dependent manner.
For clinicians in front of NMO patients, these various 
patterns must be informative. For Type 1 and 2, we should 
consider the earliest strategy to remove the humoral fac-
tors such as immunoglobulin and complement in the acute 
stage, probably by plasmapheresis [55], and to decrease 
complement activity possibly by anti-C5 antibodies [40], 
by preventing granulocyte infiltration [42, 47]. Alterna-
tively, blocking endogenous auto-antibody binding with 
aquaporumab, which binds to AQP4 but is unable to acti-
vate complement or interact with effector cells [53] may 
be beneficial. Inhibition of complement activation or 
granulocyte infiltration are promising to at least partially 
block lesion types 1–3, and thus to ameliorate acute dis-
ease exacerbations. However, it is unlikely that these treat-
ment strategies have a major effect on the lesion types 4–6, 
and therefore will not fully prevent disease progression. 
In contrast, persistent reduction of serum auto-antibody 
titers, for instance by immunosuppressive drugs or anti-
CD20 antibodies [17], or blockade of AQP4 antibody bind-
ing by small molecule inhibitors [54], may be more effec-
tive against the entire spectrum of NMO lesions. Finally, 
the presence of destructive spinal cord lesions and the 
resulting Wallerian tract degeneration may explain, why 
in NMO patients, after the improvement of motor func-
tions of transverse myelopathy, spastic paraparesis and 
pain with severe girdle sensation tend to persist chroni-
cally [18]. Finally, our current results provide further evi-
dence that NMO is a disease, which is distinctly different 
from MS, and that astrocyte injury and destruction is the 
primary event, which occurs in active lesions. However, 
the mechanisms of tissue injury are complex and effective 
neuroprotective therapy may have to target several differ-
ent mechanisms in parallel.
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